- Home
- CHRO vs SONN Comparison
CHRO vs SONN Comparison
Compare CHRO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- SONN
- Stock Information
- Founded
- CHRO 2002
- SONN N/A
- Country
- CHRO United States
- SONN United States
- Employees
- CHRO N/A
- SONN N/A
- Industry
- CHRO
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- SONN Health Care
- Exchange
- CHRO Nasdaq
- SONN Nasdaq
- Market Cap
- CHRO 7.6M
- SONN 3.8M
- IPO Year
- CHRO 2024
- SONN N/A
- Fundamental
- Price
- CHRO $1.30
- SONN $1.23
- Analyst Decision
- CHRO
- SONN Strong Buy
- Analyst Count
- CHRO 0
- SONN 1
- Target Price
- CHRO N/A
- SONN $20.00
- AVG Volume (30 Days)
- CHRO 148.8K
- SONN 50.9K
- Earning Date
- CHRO 08-12-2025
- SONN 08-13-2025
- Dividend Yield
- CHRO N/A
- SONN N/A
- EPS Growth
- CHRO N/A
- SONN N/A
- EPS
- CHRO N/A
- SONN N/A
- Revenue
- CHRO N/A
- SONN $1,000,000.00
- Revenue This Year
- CHRO N/A
- SONN $5,376.22
- Revenue Next Year
- CHRO N/A
- SONN N/A
- P/E Ratio
- CHRO N/A
- SONN N/A
- Revenue Growth
- CHRO N/A
- SONN 978.39
- 52 Week Low
- CHRO $0.45
- SONN $1.08
- 52 Week High
- CHRO $3.80
- SONN $10.02
- Technical
- Relative Strength Index (RSI)
- CHRO 59.71
- SONN 56.97
- Support Level
- CHRO $1.12
- SONN $1.10
- Resistance Level
- CHRO $1.88
- SONN $1.17
- Average True Range (ATR)
- CHRO 0.16
- SONN 0.07
- MACD
- CHRO 0.01
- SONN 0.01
- Stochastic Oscillator
- CHRO 27.37
- SONN 86.00
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.